FDA Accepts Libtayo® (cemiplimab-rwlc) for Priority Review for Advanced Cervical Cancer

TARRYTOWN, N.Y. , Sept. 28, 2021 /PRNewswire/ — European Union regulatory submission planned by end of 2021 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the supplemental Biologics License


Get every new post delivered right to your inbox.

Original Source